Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? (Q32090920)

6 July 2017

1 reference

title

Acute exacerbations of chronic bronchitis: what role for the new fluoroquinolones? (English)

1 reference

6 July 2017

1 reference

Obaji A

1

1 reference

PubMed ID

11232735

6 July 2017

Sethi S

series ordinal

2

1 reference

6 July 2017

1 January 2001

1 reference

6 July 2017

1 reference

6 July 2017

18

1 reference

6 July 2017

1

1 reference

6 July 2017

1-11

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200118010-00001

6 July 2017

0 references

cites work

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

12 December 2020

Expanding uses of fluoroquinolones: opportunities and challenges

1 reference

12 December 2020

Fluoroquinolone resistance in Streptococcus pneumoniae

1 reference

12 December 2020

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

1 reference

12 December 2020

Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program

1 reference

12 December 2020

Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

12 December 2020

Clinical pharmacology of gatifloxacin, a new fluoroquinolone

1 reference

12 December 2020

Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract

1 reference

12 December 2020

Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians.

1 reference

12 December 2020

Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study

1 reference

12 December 2020

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

1 reference

12 December 2020

QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience

1 reference

12 December 2020

The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults

1 reference

12 December 2020

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

1 reference

12 December 2020

Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers

1 reference

12 December 2020

Haemophilus influenzae localized in epithelial cell layers is shielded from antibiotics and antibody-mediated bactericidal activity.

1 reference

12 December 2020

Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

1 reference

12 December 2020

Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily

1 reference

12 December 2020

Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group

1 reference

12 December 2020

Levofloxacin and sparfloxacin: new quinolone antibiotics

1 reference

12 December 2020

Bacterial infection in chronic obstructive pulmonary disease

1 reference

12 December 2020

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections

1 reference

12 December 2020

Use of antibiotics in preventing recurrent acute otitis media and in treating otitis media with effusion. A meta-analytic attempt to resolve the brouhaha

1 reference

12 December 2020

The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone

1 reference

12 December 2020

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

1 reference

12 December 2020

A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis: the Canadian Ciprofloxacin Health Economic Study Group.

1 reference

12 December 2020

Fluoroquinolone toxicity profiles: a review focusing on newer agents

1 reference

12 December 2020

The efficacy and safety of a new ciprofloxacin suspension compared with co-amoxiclav tablets in the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis: a multicenter, double-blind, randomized, comparative study. Sparfloxacin Multicenter ABECB Study Group

1 reference

12 December 2020

Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group

1 reference

12 December 2020

Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity.

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance.

1 reference

12 December 2020

Quinolone-induced QT interval prolongation: a not-so-unexpected class effect

1 reference

12 December 2020

Therapy for pneumococcal infection at the millennium: doubts and certainties

1 reference

12 December 2020

Quinolone pharmacokinetics in the elderly

1 reference

12 December 2020

Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

12 December 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

12 December 2020

Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis

1 reference

12 December 2020

Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation

1 reference

12 December 2020

Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study

1 reference

12 December 2020

1 reference

12 December 2020

10.2165/00002512-200118010-00001

Identifiers

DOI

1 reference

PubMed ID

11232735

Dimensions Publication ID

6 July 2017

0 references

1 reference

PubMed ID

11232735